Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
TOKYO, December 6 , 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today applied for selection of the “Prime Market” segment of the Tokyo Stock Exchange, Inc. (“TSE”) as its listing market as determined at the Board of Directors Meeting held on November 19, 2021.
Astellas received the results of the initial assessment made by the TSE on July 9, 2021, confirming Astellas’ compliance with the listing requirements for the “Prime Market” in the new market segments that will be introduced on April 4, 2022 by the TSE.
Click below for a copy of the full press release
Follow us
